Reversal of hepatic fibrosis: Pathophysiological basis of antifibrotic therapies

College of Medicine, Department of Internal Medicine, Division of Gastroenterology, University of Dammam
Hepatic Medicine: Evidence and Research 07/2011; 3:69-80. DOI: 10.2147/HMER.S9051


Chronic liver injuries of different etiologies eventually lead to fibrosis, a scarring process associated with increased and altered deposition of extracellular matrix in the liver. Progression of fibrosis has a major worldwide clinical impact due to the high number of patients affected by chronic liver disease which can lead to severe complications, expensive treatment, a possible need for liver transplantation, and death. Liver fibrogenesis is characterized by activation of hepatic stellate cells and other extracellular matrix producing cells. Liver fibrosis may regress following specific therapeutic interventions. Other than removing agents causing chronic liver damage, no antifibrotic drug is currently available in clinical practice. The extent of liver fibrosis is variable between individuals, even after controlling for exogenous factors. Thus, host genetic factors are considered to play an important role in the process of liver scarring. Until recently it was believed that this process was irreversible. However, emerging experimental and clinical evidence is starting to show that even cirrhosis in its early stages is potentially reversible.

Download full-text


Available from: Mona H. Ismail MD,
  • [Show abstract] [Hide abstract]
    ABSTRACT: AimTo evaluate plasma Nogo-B levels in liver cirrhotic patients and declare a novel molecular basis by which Nogo-B modulates hepatic stellate cells (HSCs) activation. Methods Plasma Nogo-B levels from patients of liver cirrhosis were detected by enzyme-linked immuno-sorbent assay (ELISA). Rat primary HSCs were culture activated or stimulated with TGF-β. Activated HSCs were transfected for 48 hours with Nogo-B shRNA to inhibit Nogo-B expression. Gene expressions of Nogo-B, ɑ-SMA, collagen type I, TGF-β, ER stress key molecules, including CHOP, GRP78, ATF4,ATF6, Xbp-1 and calnexin, and the marker of autophagy beclin1 were detected by quantitative RT-PCR (Q-PCR). The protein expressions of Nogo-B, ɑ-SMA, collagen type I, CHOP, GRP78 and the marker of autophagy LC3B were evaluated by western blot. ResultsLiver cirrhotic patients showed a much higher level of plasma Nogo-B compared with the healthy controls. Nogo-B expression and ER stress could be induced during the process of cultured HSCs activation. TGF-β treatment increased Nogo-B expression time- and dose- dependently. Knockdown of Nogo-B in HSCs reduced the activation of HSCs. After Nogo-B gene knockdown, there was a decline of expression of ER stress markers and autophagic markers. Agonist or antagonist of ER stress could regulate autophagy level. Conclusions Circulating Nogo-B might be an effective indicator for liver cirrhosis. Nogo-B inhibition could diminish HSCs activation, in which alleviating ER stress might be one of the mechanisms, suggesting a potential approach to interference Nogo-B in liver fibrosis.
    Hepatology Research 03/2014; 45(1). DOI:10.1111/hepr.12324 · 2.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hepatic stellate cells (HSCs) are the primary source of matrix components in hepatic fibrosis. Ferulic acid (FA) has antifibrotic potential in renal and cardiac disease. However, whether FA comprises inhibitive effects of HSCs activation remains to be clarified. This study aims at evaluating the hypothesis that FA inhibits extracellular matrix (ECM)-related gene expression by the interruption of the extracellular signal-regulated kinases 1 and 2 (ERK1/2) or/and Smad signaling pathways in HSC-T6. Our results indicated that FA significantly inhibited both viability and activation of HSC-T6 cells in vitro. In addition, we demonstrated, for the first time, that FA dramatically inhibited the expression of α1(I) collagen (Col-I) and fibronectin at levels of transcription and translation. Moreover, FA treatment inhibited Smad transcriptional activity, as evaluated by transient transfection with a plasmid construction containing SMAD response element and the luciferase reporter gene. Furthermore, FA inhibition of HSCs activation involved in both focal adhesion kinase (FAK)-dependent ERK1/2 and Smad signaling pathways with independent manner. Blocking transforming growth factor-β by a neutralizing antibody caused a marked reduction in both ERK1/2 and Smad signaling. These results support FA as an effective therapeutic agent for the prevention and treatment of hepatic fibrosis.
    Biochemical Pharmacology 11/2014; 93(1). DOI:10.1016/j.bcp.2014.10.016 · 5.01 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Progressive liver fibrosis is a major health issue for which no effective treatment is available, leading to cirrhosis and orthotopic liver transplantation. However, organ shortage is a reality. Hence, there is an urgent need to find alternative therapeutic strategies. Cell-based therapy using mesenchymal stem cells (MSCs) may represent an attractive therapeutic option, based on their immunomodulatory properties, their potential to differentiate into hepatocytes, allowing the replacement of damaged hepatocytes, their potential to promote residual hepatocytes regeneration and their capacity to inhibit hepatic stellate cell activation or induce their apoptosis, particularly via paracrine mechanisms. The current review will highlight recent findings regarding the input of MSC-based therapy for the treatment of liver fibrosis, from in vitro studies to pre-clinical and clinical trials. Several studies have shown the ability of MSCs to reduce liver fibrosis and improve liver function. However, despite these promising results, some limitations need to be considered. Future prospects will also be discussed in this review.
    World Journal of Gastroenterology 01/2015; 21(3):742-758. DOI:10.3748/wjg.v21.i3.742 · 2.37 Impact Factor
Show more